Berndt Modig Sells 2,292 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $29.22, for a total value of $66,972.24. Following the completion of the sale, the chief executive officer owned 137,500 shares of the company’s stock, valued at approximately $4,017,750. This represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $28.60, for a total value of $65,551.20.
• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The stock was sold at an average price of $27.74, for a total value of $647,257.42.

Pharvaris Stock Performance

PHVS stock traded up $0.50 during midday trading on Wednesday, reaching $29.45. The company’s stock had a trading volume of 209,588 shares, compared to its average volume of 226,010. The stock has a fifty day simple moving average of $28.26 and a two-hundred day simple moving average of $26.68. Pharvaris N.V. has a 1 year low of $15.46 and a 1 year high of $33.33. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -9.26 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, analysts forecast that Pharvaris N.V. will post -3.25 EPS for the current fiscal year.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised earnings estimates for Pharvaris across several periods, including FY2026 through FY2030, while keeping a Buy rating and a $60 price target. The firm’s improved outlook suggests growing confidence in the company’s longer-term earnings potential.
• Neutral Sentiment: Pharvaris recently reported a narrower-than-expected quarterly loss, posting EPS of ($0.70) versus consensus of ($0.82). That’s supportive for sentiment, but the company remains unprofitable and still faces expected losses in the near term.
• Negative Sentiment: Two insider sales may weigh on sentiment: Director Robert Glassman sold 10,000 shares, and insider Wim Souverijns also sold 10,000 shares. Large insider selling can make investors question near-term confidence, even though the transactions were disclosed and don’t necessarily signal a fundamental problem. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System lifted its holdings in Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after acquiring an additional 520 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris during the fourth quarter worth approximately $35,000. Public Employees Retirement System of Ohio increased its position in shares of Pharvaris by 20.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on PHVS shares. Wedbush raised their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, Citizens Jmp decreased their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pharvaris has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.